An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Figure 2

Change in tumor surface area in time during BEV treatment in 15 patients evaluable on gadolinium-enhanced T1-weighted MRI. Patient no. 14 had a decrease of the measured contrast-enhancing lesion; however, a new contrast-enhancing lesion appeared in a different location.